Abstract
The new oral neuraminidase (NA) inhibitor A-322278 was evaluated in mice infected with influenza A/H1N1 wild-type virus or the oseltamivir-resistant (H274Y mutant) virus. A-322278 decreased mortality rates and lung virus titers significantly more than oseltamivir in mice infected with the NA H274Y mutant when therapy was started 4 h before or even 48 h after infection.
MeSH terms
-
Animals
-
Drug Resistance, Fungal / drug effects
-
Drug Resistance, Fungal / genetics
-
Influenza A Virus, H1N1 Subtype / drug effects*
-
Influenza A Virus, H1N1 Subtype / genetics*
-
Lung / virology
-
Mice
-
Mice, Inbred BALB C
-
Mutation / genetics
-
Neuraminidase / antagonists & inhibitors*
-
Orthomyxoviridae Infections / drug therapy
-
Orthomyxoviridae Infections / mortality
-
Orthomyxoviridae Infections / virology
-
Oseltamivir / pharmacology*
-
Pyrrolidines / pharmacology*
-
Reverse Transcriptase Polymerase Chain Reaction
-
Viral Load
Substances
-
A-322278
-
Pyrrolidines
-
Oseltamivir
-
Neuraminidase